PCPT and SELECT Cancer Cohorts
|
|
- Mercy Cannon
- 5 years ago
- Views:
Transcription
1 PCPT and SELECT Cancer Cohorts Briefly describe PCPT and SELECT trial designs Current follow-up status for each cohort SELECT Centralized Follow-up Data elements and biologic samples collected Events ascertained, verification Process for Proposing Research Using Cohorts Cathy Tangen and Phyllis Goodman, 3/24/14, Survivorship Affinity Group Presentation
2 PCPT Schema Enrollment Randomize Finasteride 5 mg Placebo Interim Prostate Cancer Lost to F/U Died Refused Biopsy For-cause Biopsy (PSA or DRE) Interim Prostate Cancer Lost to F/U Died Refused Biopsy EOS Biopsy 7-year Period Prevalence EOS Biopsy 7-year Period Prevalence
3 SELECT Schema Calendar Year (Planned ) Pre-Randomization Period Randomized Vitamin E + Vitamin E + Placebo + Placebo + Calendar Year Selenium Placebo Selenium Placebo Follow - up Prostate cancer, other cancer, death
4 Current Follow-up Status - PCPT Cancer endpoint assessment and follow-up for entire trial ended 12/03. Tried to conduct a long-term follow-up of men diagnosed with prostate cancer but proved infeasible accrual-wise. Closed 5/09 Recent SSDI search (98% of participants reported SSN) led to recent survival publication of PCPT, 3422 deaths found. Missing piece of puzzle: cause of death. Plans for NDI search, have funding. Plans to link CDMS database to evaluate longterm effects of finasteride and other research aims.
5 Current Status of Follow-up for SELECT Study site closure 6/10-4/11, close out visit Move subjects into centralized cohort followed by SWOG Statistical Center 17,747 transitioned to cohort (n=35,533 randomized) Challenge getting revised consent from participant locally and direct contact info given to Statistical Center Data collected by mailed booklets initially: cancer diagnosis, prostate cancer treatment, ancillary studies follow-up, source documents and prostate tissue requested June 2011 on-line data submission implemented Phone call primary means of contact now contracted interviewers Wrapping up final calls now, ending summer NDI search, CDMS merge plans
6 Baseline Characteristics PCPT (n=18,880) SELECT Trial (n=35,533) SELECT CFU (n=17,747) N % N % N % Age at enrollment (median [IQR],y) 63 [59-67] 62 [58-67] 62 [58-67] % 1, % % , % 11, % 5, % , % 9, % 4, % , % 6, % 3, % 70 2, % 6, % 2, % Current age (median [IQR],y) 79 [76-83] 72 [67-77] 72 [68-77] % 12, % 6, % , % 14, % 8, % , % 4, % 2, % % % % N/A (Deceased) 4, % 3, % % Race/Ethnicity White 17, % 27, % 14, % African American % 4, % 1, % Hispanic (not AA) % 1, % % Hispanic (AA) % % % Other % % %
7 Baseline Characteristics PCPT (n=18,880) SELECT Trial (n=35,533) SELECT CFU (n=17,747) N % N % N % History of prostate cancer in 1 st 2, % 6, % 3, % degree relative PSA at entry (median [IQR], ng/ml) 1.1 [ ] 1.1 [ ] 1.1 [ ] 0-<1.0 9, % 17, % 8, % 1.0-<2.0 6, % 10, % 5, % 2.0-<3.0 3, % 4, % 2, % 3.0-< % 2, % 1, % Education (highest level) High school graduate or GED 3, % 8, % 2, % Some college/vocational school 5, % 9, % 4, % College graduate 9, % 17, % 10, % Cigarette smoking Never 6, % 15, % 8, % Former 11, % 17, % 8, % Current 1, % 2, % 1, % Body mass index (kg/m 2 ) <25 4, % 7, % 3, % 25-<30 9, % 16, % 8, % 30 4, % 11, % 5, %
8 PCPT: Review of Other Cancers and Deaths Cancer reported by participant to Study Site Study Site learns of participant death Source documentation obtained and submitted to Statistical Center Additional deaths from Social Security Death Index (SSDI) and planned National Death Index search Endpoint Review Committee reviews documentation and codes cancer site/cause of death Endpoint form submitted
9 SELECT: Data Collection for Other Cancers and Deaths Other cancers Reported by the participant to study site staff Source documentation submitted to the Statistical Center Upon the interest of an investigator, source documents can be reviewed and coded Deaths Sites collected source documentation for coding cause of death on study forms Source documentation was not submitted to the Statistical Center Social Security Death Index (SSDI) search was performed in 2012 National Death Index search planned
10 Baseline Data Collected Medical history, limited Physical Exam, height, weight, demographics PCPT SELECT Trial Quality of Life (SF-36) Subset Family history cancer Prostate only Prostate, lung, colon Anthropometric measures PSA Measured at Participant report or central facility done at study site Diet and supplement use At year 1 Physical activity
11 PCPT SELECT Trial SELECT CFU Frequency Every 3 months Every 6 months Annual Medical events/side effects Medications Limited Extensive Prostate health (annually) AUA symptom score PSA and DRE (annually) Follow-Up Data Collected (annually) PSA measured at central facility; DRE by study site Participant report or done at study site Updated supplement use Adherence assessment Updated smoking history Weight Quality of Life (SF-36) On subset Macular degeneration, diabetes, colorectal screen procedures Finasteride, statins, aspirin, NSAIDs PSA, treatments for men diagnosed with prostate cancer
12 Epidemiologic Sub-studies Nested Within PCPT and SELECT Case-control study within PCPT: Approx prostate cancer cases and 1800 biopsy proven controls at 7 yrs. Frequency matched on treatment arm, family history of CaP and age group. Over-sampled African Americans Case-cohort within SELECT: cases= all prostate cancers, cohort stratified on age group and race (AA vs. not) was selected, sampling weights needed
13 Samples Collected Plasma Serum RBC WBC Prostate tissue Toenail PCPT Blood sample at baseline Annually during follow-up X x x Blood sample at baseline and Year 5 7.8% subset at 6 months, SELECT Year 1, 2, 4, 6 and 8; post-diagnostic sample for those with prostate cancer. Toenails at baseline. X x x x X WBC = white blood cell/buffy coat, RBC=red blood cell
14 SELECT: Cancers and Samples Collected Cancer site Total reported Some source documentation Baseline plasma Year 5 plasma Total with Buffy Coat available specimen specimen 2 Prostate 1 2,494 2,012 2,321 1,710 2,370 Bladder Colorectal Lung Melanoma Pancreatic Renal Other cancers Non-cancers 30,948 N/A 27,934 19,424 28,406
15 PCPT: Cancers and Samples Collected Serum Samples # Additional Pre-diagnostic Serum Samples DNA source Cancer site Total Baseline DNA Serum 1 Prostate 2,401 2, ,111 1, Bladder Colorectal Lung Melanoma Pancreatic Renal Other Non-cancers 15,301 14, , ,885 7,845 5,757 1 Among cases with no WBC or DNA available
16 Data Request Process Brief description of proposed data for epidemiologic or statistical research Approximately 2 pages Specific aims Data elements required PCPT/SELECT Cohorts Executive Committee Availability of data Overlap with other approved projects SWOG Executive Committee Review for regulatory issues Meets weekly Data Usage Agreement Who will have access to the individual participant data Data not to be shared with others or used for other projects
17 Biologic Specimens Requests SWOG webpage ( Visitors Biospecimens Application not to exceed 5 pages: Specific aims Background and significance Preliminary results (if available) Experimental methods and design Type and volume of samples Why are the PCPT/SELECT specimens and associated clinical data necessary Why is the use of the SELECT/PCPT biorepository needed or advantageous. PCPT/SELECT Cohorts Executive Committee Feasibility (population, study design, sample size, sample and data needs) Availability of biospecimens Overlap with other approved projects SWOG Executive Committee Further scientific review Meets weekly Materials reserved for 3 years Letter of support from SWOG for any applications for funding (i.e. R01s, DoD) SWOG will work with the investigator to obtain external funding Material Usage Agreements and Data Usage Agreements (local IRB approval)
18 Deaths PCPT SELECT Deaths Total 5,125 3,071 Prostate cancer Other cancer Cardiovascular Other Unknown/SSDI* 3, * Planned NDI search for cause
19 Summary: Endpoint Assessments Prostate cancer Other cancer PCPT SELECT Trial SELECT CFU Study site report Participant report; confirmed by central Medical records/tissue lab requested End of study biopsy and interim cancers Source docs collected, adjudicated Source docs collected, not adjudicated Participant report; Medical records requested Source docs collected, SSDI, NDI Deaths Site reports; SSDI adjudicated; SSDI Cardiovascular Participant report Participant report None
20
21
22
23 Unique Features of Cohorts Follow-up: median 9 yrs. SELECT, 17 yrs. PCPT 15% AA participation in SELECT Test and validation with both cohorts Nested case-control and case-cohort studies with measures stored at Statistical Center Longitudinal QOL assessment Careful longitudinal assessment of meds and dietary supplements on SELECT RCT underpinnings with significant treatment results may provide keys to mechanistic pathways
24 Resources for Future Research Upcoming National Death Index Search for PCPT and SELECT SWOG has access to CDMS database Link procedures and medications, long-term effects to both trials/cohorts. Contribute to NCI Cancer Cohort Consortium approved projects Solicit projects from scientific community, TM and data analyses, collaborate on grants WHI strategic collaborations
Selenium and Vitamin E Cancer Prevention Trial (SELECT): Questions and Answers
1 FOR IMMEDIATE RELEASE: Monday, October 27, 2008 CONTACT: NCI Office of Media Relations (301) 496-6641 ncipressofficers@mail.nih.gov University of Michigan Nicole Fawcett (734) 764-2220 nfawcett@med.umich.edu
More informationPoint-Counterpoint: Screening does not impact mortality rates! 1989-Fast forward, what happened?
Point-Counterpoint: Early Detection of Prostate Cancer Is Not Valuable We Can t Go Backwards Of Course Screening Has Saved Lives ~ Robert E. Donohue, MD Screening does not impact mortality rates! E. David
More informationAvailable for Public Disclosure Without Redaction
PROSCAR (finasteride 5 mg) Supplemental New Drug Application Prostate Cancer Prevention Trial Oncologic Drugs Advisory Committee Briefing Document Presented to ODAC on 01-December 2010 Available for Public
More informationRapid Case Ascertainment in Population and Hospital- Based Studies: Notes From the Field
Rapid Case Ascertainment in Population and Hospital- Based Studies: Notes From the Field James R. Cerhan, M.D., Ph.D. Mayo Clinic College of Medicine University of Iowa College of Public Health Overview
More informationCCC update. WHI Investigators Meeting May 7-8, 2015
CCC update WHI Investigators Meeting May 7-8, 2015 Significant activities of the past year RFP and responses for 2015-2020 Extension study Preparation for launching two new embedded trials Significant
More informationCONTRACTING ORGANIZATION: Johns Hopkins Bloomberg School of Public Health
AD Award Number: W81XWH-12-1-0170 TITLE: Prospective Evaluation of Intraprostatic Inflammation and Focal Atrophy as a Predictor of Risk of High-Grade Prostate Cancer and Recurrence after Prostatectomy
More information8/10/2012. Education level and diabetes risk: The EPIC-InterAct study AIM. Background. Case-cohort design. Int J Epidemiol 2012 (in press)
Education level and diabetes risk: The EPIC-InterAct study 50 authors from European countries Int J Epidemiol 2012 (in press) Background Type 2 diabetes mellitus (T2DM) is one of the most common chronic
More informationProstate Cancer Incidence
Prostate Cancer: Prevention, Screening and Treatment Philip Kantoff MD Dana-Farber Cancer Institute Professor of fmedicine i Harvard Medical School Prostate Cancer Incidence # of patients 350,000 New Cases
More informationPCaP Snapshot. Baseline Data Collection
From the Guidelines for Use of Data and Biospecimens North Carolina Louisiana Prostate Cancer Project (PCaP) Funded by the Department of Defense contract DAMD 17-03-2-0052 See Data Use Guide for more detail.
More informationNational Lung Screening Trial Results
National Lung Screening Trial Results Ella A. Kazerooni, M.D. Professor & Director Cardiothoracic Radiology Associate Chair for Clinical Affairs University of Michigan NLST STOPPED! Lung cancer trial results
More informationFinal Report 22 January 2014
Final Report 22 January 2014 Cohort Study of Pioglitazone and Cancer Incidence in Patients with Diabetes Mellitus, Follow-up 1997-2012 Kaiser Permanente Division of Research Assiamira Ferrara, MD, Ph.D.
More informationPresentation for DHSS 14 September Senior Statistician
Presentation for DHSS 14 September 2014 Jeannette Jackson-Thompson, MSPH, PhD Director Chester Schmaltz, PhD Senior Statistician Missouri Cancer Registry and Research Center (MCR-ARC) University of Missouri
More informationCHRONIC HEPATITIS B AND C COHORT STUDY (CHECS)
CHRONIC HEPATITIS B AND C COHORT STUDY (CHECS) CDC CONTACT Scott D Holmberg, M.D., M.P.H. Chief, Epidemiology and Surveillance Branch Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis,
More information6/6/2011. Recruitment methods employed in the. Pamela Marcus, PhD. National Cancer Institute NLST
Recruitment methods employed in the National Lung Screening Trial (NLST) Pamela Marcus, PhD Division of Cancer Prevention National Cancer Institute NLST 1 NLST: The basics Sponsored by the US National
More informationMarian L Neuhouser, PhD, RD
Marian L Neuhouser, PhD, RD Dietary Supplements and Cancer Risk Cancer Prevention Program Division of Public Health Sciences Fred Hutchinson Cancer Research Center American Institute for Cancer Research
More informationPhysical activity, Obesity, Diet and Colorectal Cancer Prognosis. Jeffrey Meyerhardt, MD, MPH Dana-Farber Cancer Institute Boston, MA
Physical activity, Obesity, Diet and Colorectal Cancer Prognosis Jeffrey Meyerhardt, MD, MPH Dana-Farber Cancer Institute Boston, MA Colorectal Cancer Incidence ~148,000 cases in US annually and ~50,000
More informationScreening for Disease
Screening for Disease An Ounce of Prevention is Worth a Pound of Cure. Actually, an ounce of prevention is better than a pound of cure, but if prevention hasn t been effective, perhaps early identification
More informationBurden of Cancer in California
Burden of Cancer in California California Cancer Reporting and Epidemiologic Surveillance Institute for Population Health Improvement UC Davis Health August 22, 2018 Outline 1. Incidence and Mortality
More informationEffect of Selenium and Vitamin E on Risk of Prostate Cancer and Other Cancers JAMA. 2009;301(1):39-51
ORIGINAL CONTRIBUTION JAMA-EXPRESS Effect of and on Risk of Prostate Cancer and Other Cancers The and Cancer Prevention Trial (SELECT) Scott M. Lippman, MD Eric A. Klein, MD Phyllis J. Goodman, MS M. Scott
More informationBPH with persistently elevated PSA 아주대학교김선일
BPH with persistently elevated PSA 아주대학교김선일 PSA in BPH: present status AUA & EAU BPH guideline: PSA: recommended test AUA practice guideline committee. J Urol 2003;170:530 Madersbacher. Eur Urol 2004;46:547
More informationDesign considerations for Phase II trials incorporating biomarkers
Design considerations for Phase II trials incorporating biomarkers Sumithra J. Mandrekar Professor of Biostatistics, Mayo Clinic Pre-Meeting Workshop Enhancing the Design and Conduct of Phase II Studies
More informationProstate Cancer Screening: Risks and Benefits across the Ages
Prostate Cancer Screening: Risks and Benefits across the Ages 7 th Annual Symposium on Men s Health Continuing Progress: New Gains, New Challenges June 10, 2009 Michael J. Barry, MD General Medicine Unit
More informationPSA levels during midlife and risk of aggressive prostate cancer in African American men
PSA levels during midlife and risk of aggressive prostate cancer in African American men Kathryn Wilson, Sc.D. Research Scientist Department of Epidemiology PHEN 12th Annual African American Prostate Cancer
More informationOncology Clinical Research & Race: Statistical Principles
Oncology Clinical Research & Race: Statistical Principles Daniel Sargent, PhD ALLIANCE Group Statistician November 2014 The Literary Digest predicted Alf Landon would win the presidency in 1936 1936 PRESIDENTIAL
More informationUpdates In Cancer Screening: Navigating a Changing Landscape
Updates In Cancer Screening: Navigating a Changing Landscape Niharika Dixit, MD I have no conflict of interest. 1 Why Should You Care Trends in Cancer Incidence by Site United States. Siegal Et al: CA
More informationNational Cancer Institute
National Cancer Institute U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Cancer Institute Community Oncology Research Program (NCORP) Institute of Medicine Implementing
More informationJ Clin Oncol 25: by American Society of Clinical Oncology INTRODUCTION
VOLUME 25 NUMBER 21 JULY 20 2007 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Prediction of Prostate Cancer for Patients Receiving Finasteride: Results From the Prostate Cancer Prevention Trial
More informationThe Clinical Research E-News
ISSUE 18: September 9, 2009 New Activations: The Clinical Research E-News SWOG0518, Phase III Prospective Randomized Comparison of Depot Octreotide Plus Interferon Alpha Versus Depot Octreotide Plus Bevacizumab
More informationLife Sciences Consortium Task Force Report to The National Cancer Policy Forum Workshop
Life Sciences Consortium Task Force Report to The National Cancer Policy Forum Workshop Gregory A. Curt, MD, Chair U.S. Medical Science Lead, Emerging Products AstraZeneca -Oncology CEO Roundtable-I May
More informationContemporary Approaches to Screening for Prostate Cancer
Contemporary Approaches to Screening for Prostate Cancer Gerald L. Andriole, MD Robert K. Royce Distinguished Professor Chief of Urologic Surgery Siteman Cancer Center Washington University School of Medicine
More informationClinical Trial Recruitment Process Randomized Clinical Trials. Source: Cary P Gross. Annals of Internal Medicine. July 2, Vol. 137, Number 1.
Cancer Clinical Trials (CCT) Attitudes and Awareness Among Cancer Survivors Clinical trials are essential for the identification of effective therapies in modern medicine. A number of studies have found
More informationThe Multiethnic Cohort Study: Studying Ethnic Diversity and Cancer. Laurence N. Kolonel, MD, PhD
The Multiethnic Cohort Study: Studying Ethnic Diversity and Cancer Laurence N. Kolonel, MD, PhD Background of the Multiethnic Cohort Study (MEC) Features of the Design Multiethnic: Five groups in Hawaii
More informationSelenium and Vitamin E Cancer Prevention Trial (SELECT): Questions and Answers. Key Points
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Selenium and Vitamin E
More informationPotential Opportunities for Collaboration with Pancreatic U01s
Potential Opportunities for Collaboration with Pancreatic U01s Sudhir Srivastava, PhD, MPH Chief, Cancer Biomarkers Research Group Division of Cancer Prevention Background Recalcitrant Cancer Research
More informationResearch For the Future. Len Lichtenfeld, MD, MACP Interim Chief Medical and Scientific Officer
Research For the Future Len Lichtenfeld, MD, MACP Interim Chief Medical and Scientific Officer 1 2 ATTACKING CANCER FROM EVERY ANGLE 3 CANCER PREVENTION STUDIES (CPS) Intramural Research Smoking Obesity
More informationSetting The setting was primary care. The economic study was conducted in the USA.
Lifetime implications and cost-effectiveness of using finasteride to prevent prostate cancer Zeliadt S B, Etzioni R D, Penson D F, Thompson I M, Ramsey S D Record Status This is a critical abstract of
More informationPROSTATE CANCER Amit Gupta MD MPH
PROSTATE CANCER Amit Gupta MD MPH Depts. of Urology and Epidemiology Amit-Gupta-1@uiowa.edu dramitgupta@gmail.com Tel: 319-384-5251 OUTLINE PSA screening controversy How to use PSA more effectively Treatment
More informationChester Schmaltz, PhD Dept. of Health Management & Informatics, School of Medicine Missouri Cancer Registry and Research Center (MCR-ARC) University
Chester Schmaltz, PhD Dept. of Health Management & Informatics, School of Medicine Missouri Cancer Registry and Research Center (MCR-ARC) University of Missouri Columbia Chester Schmaltz, PhD The following
More informationThe contribution of the population biobank of ISPO
The contribution of the population biobank of ISPO Domenico Palli Molecular and Nutritional Epidemiology Unit - ISPO, Florence d.palli@ispo.toscana.it 9 March 2012, Rome Challenges and Opportunities of
More informationHighlights from the NCORP Committees
Highlights from the NCORP Committees Prevention and Epidemiology Co-chairs: Marian Neuhouser, Banu Arun Survivorship Co-chair: Robert Krouse Katherine Crew, MD, MS October 13, 2017 Outline Prevention and
More informationFinasteride Does Not Increase the Risk of High-grade Prostate Cancer: A Biasadjusted. Mary W. Redman, Ph.D. 1. Catherine M. Tangen, Dr.
Finasteride Does Not Increase the Risk of High-grade Prostate Cancer: A Biasadjusted Modeling Approach Mary W. Redman, Ph.D. 1 Catherine M. Tangen, Dr. PH 1 Phyllis J. Goodman, MS 1 Howard Parnes, M.D.
More informationEthnic Minority RA Consortium (EMRAC)
Ethnic Minority RA Consortium (EMRAC) Yusuf Yazıcı, MD Assistant Professor of Medicine, New York University School of Medicine Director, Seligman Center for Advanced Therapeutics & Behçet Syndrome Evaluation,
More informationResponse to United States Preventative Services Task Force draft PSA Screening recommendation: Donald B. Fuller, M.D. Genesis Healthcare Partners
Response to United States Preventative Services Task Force draft PSA Screening recommendation: Donald B. Fuller, M.D. Genesis Healthcare Partners October 2011 Cancer Incidence Statistics, 2011 CA: A Cancer
More informationIron status and novel risk factors for iron depletion in a diverse donor population
Iron status and novel risk factors for iron depletion in a diverse donor population 1 Bryan Spencer, Yuelong Guo, Ritchard Cable, Joseph Kiss, Michael Busch, Grier Page, Stacy Endres-Dighe, Steve Kleinman,
More informationCan aspirin slow cognitive decline and the onset of dementia? The ASPREE study. Mark Nelson on behalf of ASPREE Investigators
Can aspirin slow cognitive decline and the onset of dementia? The ASPREE study. Mark Nelson on behalf of ASPREE Investigators ASPREE Randomized, double-blind, placebo-controlled trial for extending healthy
More informationSummary of Phase 3 IMPACT Trial Results Presented at AUA Meeting Webcast Conference Call April 28, Nasdaq: DNDN
Summary of Phase 3 IMPACT Trial Results Presented at AUA Meeting Webcast Conference Call April 28, 2009 Nasdaq: DNDN PROVENGE sipuleucel-t is an autologous active cellular immunotherapy that activates
More informationPSA To screen or not to screen? Darrel Drachenberg, MD, FRCSC
PSA To screen or not to screen? Darrel Drachenberg, MD, FRCSC Disclosures Faculty / Speaker s name: Darrel Drachenberg Relationships with commercial interests: Grants/Research Support: None Speakers Bureau/Honoraria:
More informationInnovator Case Studies: Oncology Networks
Innovator Case Studies: Oncology Networks J. Ike Nicoll Chief Executive Officer Cancer Clinics of Excellence Alan Armer, Ph.D. Vice President, Research & Development Catholic Health Initiatives Cancer
More informationProstate Cancer: from Beginning to End
Prostate Cancer: from Beginning to End Matthew D. Katz, M.D. Assistant Professor Urologic Oncology Robotic and Laparoscopic Surgery University of Arkansas for Medical Sciences Winthrop P. Rockefeller Cancer
More informationStrategic Peer-Enhanced Care and Treatment Retention Model (SPECTRuM) Initiative. Intervention Protocol #2
MASSACHUSETTS DEPARTMENT OF PUBLIC HEALTH BUREAU OF INFECTIOUS DISEASE AND LABORATORY SCIENCES HIV/AIDS AND STD SURVEILLANCE PROGRAM AND OFFICE OF HIV/AIDS Strategic Peer-Enhanced Care and Treatment Retention
More informationUpdate on vitamin D. J Chris Gallagher Professor of Medicine and Endocrinology Creighton University Omaha,Nebraska USA
Update on vitamin D J Chris Gallagher Professor of Medicine and Endocrinology Creighton University Omaha,Nebraska 68131 USA Cali, Colombia 2016 definitions DRIs are the recommended dietary reference intakes
More informationCHARACTERISTICS OF NHANES CHILDREN AND ADULTS WHO CONSUMED GREATER THAN OR EQUAL TO 50% OF THEIR CALORIES/DAY FROM SUGAR AND THOSE WHO DO NOT
CHARACTERISTICS OF NHANES CHILDREN AND ADULTS WHO CONSUMED GREATER THAN OR EQUAL TO 50% OF THEIR CALORIES/DAY FROM SUGAR AND THOSE WHO DO NOT Data from the National Health and Nutrition Examination Survey
More informationAccelerating Innovation in Statistical Design
Implementing a National Cancer Clinical Trials System for the 21 st Century, Workshop #2 Session #5: Accelerating Innovation Through Effective Partnerships Accelerating Innovation in Statistical Design
More informationOpportunities and challenges in incorporating ancillary studies into a cancer prevention randomized clinical trial
Opportunities and challenges in incorporating ancillary studies into a cancer prevention randomized clinical trial The Harvard community has made this article openly available. Please share how this access
More informationSUPPLEMENTAL MATERIAL
SUPPLEMENTAL MATERIAL Supplemental Table 1. Distribution of Participants Characteristics by Treatment Group at Baseline - The Vitamin D and calcium (CaD) Trial of the Women s Health Initiative (WHI) Study,
More informationEarly Chemotherapy for Metastatic Prostate Cancer
Early Chemotherapy for Metastatic Prostate Cancer Daniel P. Petrylak, MD Professor of Medicine and Urology Smilow Cancer Center Yale University Medical Center Disclosure Consultant: Sanofi Aventis, Celgene,
More informationADVANCING CANCER RESEARCH THROUGH A VIRTUAL POOLED REGISTRY. Dennis Deapen, DrPH NAACCR Annual Meeting June 16, 2015 Charlotte, NC
ADVANCING CANCER RESEARCH THROUGH A VIRTUAL POOLED REGISTRY Dennis Deapen, DrPH NAACCR Annual Meeting June 16, 2015 Charlotte, NC 1 THE OPPORTUNITY Cancer epidemiology cohort studies may have participants
More informationDesign and Analysis of a Cancer Prevention Trial: Plans and Results. Matthew Somerville 09 November 2009
Design and Analysis of a Cancer Prevention Trial: Plans and Results Matthew Somerville 09 November 2009 Overview Objective: Review the planned analyses for a large prostate cancer prevention study and
More informationComparison And Application Of Methods To Address Confounding By Indication In Non- Randomized Clinical Studies
University of Massachusetts Amherst ScholarWorks@UMass Amherst Masters Theses 1911 - February 2014 Dissertations and Theses 2013 Comparison And Application Of Methods To Address Confounding By Indication
More informationNational Cancer Policy Forum Workshop on Multi-Center Phase 3 Clinical Trials and NCI Cooperative Groups
National Cancer Policy Forum Workshop on Multi-Center Phase 3 Clinical Trials and NCI Cooperative Groups Session 3: Data Collection Standards to Establish Safety and Efficacy: How Much Data Is Enough?
More informationEpidemiology in Texas 2006 Annual Report. Cancer
Epidemiology in Texas 2006 Annual Report Cancer Epidemiology in Texas 2006 Annual Report Page 94 Cancer Incidence and Mortality in Texas, 2000-2004 The Texas Department of State Health Services Texas Cancer
More informationWhere are we going after effectiveness studies?
Where are we going after effectiveness studies? Nyaradzo M. Mgodi (MBChB, MMed) UZ-UCSF Collaborative Research Program Harare, Zimbabwe MTN Annual Meeting 28 March 2011, Arlington, VA Introduction 30 years
More informationProstate Cancer Screening. Dickon Hayne University of Western Australia
Prostate Cancer Screening Dickon Hayne University of Western Australia JMG Wilson & G Junger, WHO, 1968 p26-27 In theory, therefore, screening is an admirable method of combating disease, since it should
More informationLessons learned for the conduct of a successful screening trial
Lessons learned for the conduct of a successful screening trial Christine D. Berg, M.D. Adjunct Professor Department of Radiation Oncology Johns Hopkins Medicine IOM State of the Science in Ovarian Cancer
More informationResearch opportunities in UK Biobank
Research opportunities in UK Biobank Cancer Outcomes Conference June 2012 Cathie Sudlow Reader and Honorary Consultant Neurologist, University of Edinburgh Chief Scientist and Senior Epidemiologist, UK
More informationAction to Cure Kidney Cancer Campaign to Fund Kidney Cancer Research
Action to Cure Kidney Cancer 2016 Campaign to Fund Kidney Cancer Research Kidney Cancer Facts 9 th most common cancer in the U.S. Until recently, 3 rd highest rate of increasing incidence of all cancers
More informationCVIM s Cancer Screening Practices
12-13-17 Professional Practice Minutes CVIM s Cancer Screening Practices At CVIM, preventative health care is very important! In these minutes you will find a review of our recommendations for cancer screening
More informationThe Use of Clinical Trial Data in Combination with External Data Sources to Examine Novel Cancer Research Questions: A Modified Big Data Approach
The Use of Clinical Trial Data in Combination with External Data Sources to Examine Novel Cancer Research Questions: A Modified Big Data Approach Joseph Unger, Ph.D. Assistant Member, Public Health Sciences
More informationPrevention What It s All About
Prevention What It s All About Dr James Schuppert Director, January 14, 2015 Information Security This presentation contains Corning Restricted information and is intended solely for those with a need
More informationTiming of Androgen Deprivation: The Modern Debate Must be conducted in the following Contexts: 1. Clinical States Model
Timing and Type of Androgen Deprivation Charles J. Ryan MD Associate Professor of Clinical Medicine UCSF Comprehensive Cancer Center Timing of Androgen Deprivation: The Modern Debate Must be conducted
More informationTITLE: Long Term Outcomes of BRCA1/BRCA2 Mutation Testing. CONTRACTING ORGANIZATION: Georgetown University Washington, DC
AD AWARD NUMBER: DAMD17-03-1-0553 TITLE: Long Term Outcomes of BRCA1/BRCA2 Mutation Testing PRINCIPAL INVESTIGATOR: Marc D. Schwartz, Ph.D. CONTRACTING ORGANIZATION: Georgetown University Washington, DC
More informationQuestionnaire. 1) Do you see men over the age of 40? 1. Yes 2. No
Questionnaire 1) Do you see men over the age of 40? 1. Yes 2. No 2) In what state do you practice? (drop-down menu of 50 states and District of Columbia) 3) What is your medical specialty? (Please select
More informationCharacteristics of Philadelphia Census Tracts with High Prostate Cancer Risk
Characteristics of Philadelphia Census Tracts with High Prostate Cancer Risk Charnita Zeigler-Johnson, PhD, MPH Thomas Jefferson University Philadelphia, PA Using Cancer Registry Data in Disparities Research
More informationWomen s Health Study Matrix of Variables Collected
Women s Health Study Matrix of Variables Collected 1. Demography DOB SS# Marital status Gender Race Profession Education NHS participant Income Employment status Phone number Contacts 2. Anthropometry
More informationProstate Cancer. Dr. Andres Wiernik 2017
Prostate Cancer Dr. Andres Wiernik 2017 Objectives YES!!! 1. Epidemiology 2. Biology or Natural History of Prostate Cancer 3. Treatment NO!!! 1. Prostate Cancer Screening - controversies Which is the most
More informationThe Linked SEER-Medicare Data and Cancer Effectiveness Research
The Linked SEER-Medicare Data and Cancer Effectiveness Research Arnold L. Potosky, PhD Professor of Oncology Director of Health Services Research Georgetown University Medical Center Lombardi Comprehensive
More informationCHAPTER 7 SECTION 24.1 PHASE I, PHASE II, AND PHASE III CANCER CLINICAL TRIALS TRICARE POLICY MANUAL M, AUGUST 1, 2002 MEDICINE
MEDICINE CHAPTER 7 SECTION 24.1 ISSUE DATE: AUTHORITY: 32 CFR 199.4(e)(26) I. DESCRIPTION The Department of Defense (DoD) Cancer Prevention and Treatment Clinical Trials Demonstration was conducted from
More informationOncolytic Viruses: Reovirus
T S X : O N C N A S D A Q : O N C Y International Society for Biological Therapy of Cancer 2008 Oncology Biologics Development Primer Oncolytic Viruses: Reovirus REOLYSIN - mode of action REOLYSIN contains
More informationQuality of Life and Trial Adherence Among Participants in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial
Quality of Life and Trial Adherence Among Participants in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Kathryn L. Taylor, Rebecca Shelby, Edward Gelmann, Colleen McGuire Background:
More informationTITLE: A Phase II Trial of Androgen Suppression and Radiation Therapy with Samarium-1 53 in Localized, High-Risk, Prostate Cancer
AD Award Number: W81XWH-04-1-0769 TITLE: A Phase II Trial of Androgen Suppression and Radiation Therapy with Samarium-1 53 in Localized, High-Risk, Prostate Cancer PRINCIPAL INVESTIGATOR: Richard K. Valicenti,
More informationThe COSMOS Trial. (COcoa Supplement and Multivitamins Outcomes Study) JoAnn E. Manson, MD, DrPH Howard D. Sesso, ScD, MPH
COSMOS Trial The COSMOS Trial (COcoa Supplement and Multivitamins Outcomes Study) JoAnn E. Manson, MD, DrPH Howard D. Sesso, ScD, MPH Brigham and Women's Hospital Harvard Medical School Garnet L. Anderson,
More informationIn this second module in the clinical trials series, we will focus on design considerations for Phase III clinical trials. Phase III clinical trials
In this second module in the clinical trials series, we will focus on design considerations for Phase III clinical trials. Phase III clinical trials are comparative, large scale studies that typically
More informationTHE BURDEN OF CANCER IN NEBRASKA: RECENT INCIDENCE AND MORTALITY DATA
THE BURDEN OF CANCER IN NEBRASKA: RECENT INCIDENCE AND MORTALITY DATA Presented by: Bryan Rettig, MS Nebraska Dept. of Health & Human Services Division of Public Health May 31, 2017 Nebraska Cancer Registry
More informationChemoprevention. Chemoprevention is the use of natural or synthetic substances to reduce the risk of
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Chemoprevention Chemoprevention
More informationNCI/Local Protocol #: RTOG-0521/RTOG NCI Protocol Version Date: December 22, 2014 (Broadcast date: 2/2/2015)
For Protocol Amendment 7of RTOG 0521, A Phase III Protocol of Androgen Suppression (As) And 3DCRT/IMRT Vs. As And 3DCRT/IMRT Followed By Chemotherapy With Docetaxel And Prednisone For Localized, High-Risk
More informationFinancial Disclosure. Learning Objectives. Review and Impact of the NCDB PUF. Moderator: Sandra Wong, MD, MS, FACS, FASCO
Review and Impact of the NCDB PUF Moderator: Sandra Wong, MD, MS, FACS, FASCO Financial Disclosure I do not have personal financial relationships with any commercial interests Learning Objectives At the
More informationCancer Prevention. Underlying Assumptions. Other Known Risk Factors. Other Known Risk Factors 6/25/2009
Underlying Assumptions Cancer Prevention Judith A. Luce, M.D. jluce@hemeonc.ucsf.edu The Model of Carcinogenesis Multistep, multiple mutations Takes years: peak annual risk @ 70+ yrs Accelerated by genetic
More informationGSK Medicine: Study No.: Title: Rationale: Objectives: Indication: Study Investigators/Centers: Research Methods:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationHealth care reform: Continuing the prostate screening debate; Where does patient navigation belong?
University of Arkansas for Medical Sciences From the SelectedWorks of Michael Preston November 4, 2013 Health care reform: Continuing the prostate screening debate; Where does patient navigation belong?
More informationOVERALL HEALTH EFFECTS OF SWEDISH MATCH SNUS PRODUCTS
OVERALL HEALTH EFFECTS OF SWEDISH MATCH SNUS PRODUCTS Lester Jao Lacorte, MD, CCRP Medical Officer Office of Science Center for Tobacco Products U.S. Food and Drug Administration DISCLAIMER 1 The information
More informationMultidisciplinary Quality of Life Intervention for Men with Biochemical Recurrence of Prostate Cancer
Multidisciplinary Quality of Life Intervention for Men with Biochemical Recurrence of Prostate Cancer Steven C. Ames, PhD, ABPP Division of Hematology & Oncology Investigative Team Winston W. Tan, MD Mayo
More informationChemoprevention Prostate Cancer
Chemoprevention Prostate Cancer E. David Crawford, MD Professor of Surgery (Urology) and Radiation Oncology Head, Urologic Oncology E. David Crawford Endowed Chair in Urologic Oncology University of Colorado
More informationCalifornia Pacific Medical Center Research Institute:
Wake Forest University Health Sciences: Laura D. Baker, PhD Sally Shumaker, PhD Stephen Rapp, PhD Beverly Snively, PhD Daniel Beavers, PhD Kate Hayden, PhD Emily Gower, PhD Kaycee Sink, MD Bonnie Sachs,
More informationThe Murtha Cancer Center 2nd Annual Cancer Research Seminar Walter Reed National Military Medical Center Bethesda, MD June 23, 2014
The Murtha Cancer Center 2nd Annual Cancer Research Seminar Walter Reed National Military Medical Center Bethesda, MD June 23, 2014 Center for Prostate Disease Research (CPDR) Overview and Research Highlights
More informationOtis W. Brawley, MD, MACP, FASCO, FACE
Otis W. Brawley, MD, MACP, FASCO, FACE Chief Medical and Scientific Officer American Cancer Society Professor of Hematology, Medical Oncology, Medicine and Epidemiology Emory University Atlanta, Georgia
More informationMATERIALS AND METHODS
Primary Triple Androgen Blockade (TAB) followed by Finasteride Maintenance (FM) for clinically localized prostate cancer (CL-PC): Long term follow-up and quality of life (QOL) SJ Tucker, JN Roundy, RL
More informationDRAFT. Table Cohort studies on smoking and risk of colorectal cancer. Cohort description. No of cases. Smoking categories
Terry et al. (2002), USA, Canadian National Breast Screening Study (NBSS) Tiemersma et al. (2002), Netherlands, Monitoring Project on Cardiovascular Disease Risk Factors Multicenter randomized controlled
More informationRyan White Enrollment within the CAPUS Demonstration Project
Ryan White Enrollment within the CAPUS Demonstration Project Virtual Administrative Reverse Site Visit February 5, 2016 Tonya King Jalesa Sutton Veronica Calvin Objectives At the end of this presentation
More informationKnowledge, Attitude, Self-Efficacy, Literacy and CRC Screening in Rural Community Clinics
Knowledge, Attitude, Self-Efficacy, Literacy and CRC Screening in Rural Community Clinics Connie Arnold, PhD LSU Health Sciences Center Shreveport Alfred Rademaker, PhD Northwestern University Terry Davis,
More information